Many people working in the nutrition industry feel positive about the EU’s new process for the approval of novel foods, new research by the organisers of Vitafoods Europe shows. However, experts are warning that there could be adverse implications for some companies’ intellectual property portfolios.
The new regulations on novel foods, defined as anything without a significant history of consumption in the EU before 15 May 1997, come into force on 1 January 2018. For the first time, the approval system will be centralised with applications submitted to the European Commission rather than individual member states.
There appears to be a degree of optimism about the new regime. A fifth (20 per cent) of industry professionals surveyed by the organisers of Vitafoods Europe said they thought the new rules would have a positive impact. This was double the number who expected them to have a negative impact (10 per cent).
More than a quarter of respondents (27 per cent) said they had already taken action to prepare for the new rules, while 17 per cent said they were now more likely to apply for novel foods status compared with 12 per cent who said they were less likely to do so.
A quicker process
Reforming the novel foods regulation is intended to streamline and speed up the application process. “The biggest problem with the old system was time” said Liza Van Den Eede, Regulatory Affairs Director at Pen & Tec Consulting, presents an update on the new process at Vitafoods Europe 2018. “It took an average of three and a half years to get a novel food approval and in some cases it was five or even six. The better defined deadlines in the new process, as well as the guidance from EFSA, should hopefully mean faster approvals. However, there are probably many companies that are pessimistic about the timescales based on past experience with EFSA, since unforeseen supplementary information requests can slow down the process considerably.”
Patrick Coppens, Director of Scientific & Regulatory Affairs at Food Supplements Europe, added: “On paper this is a very nice process. It’s more streamlined, it’s clearer and it should be faster. But like all legislation, the proof of the pudding is in the eating.”
Intellectual property concerns
Another key change is that authorisations will be generic. This means that once a novel food is approved it will in most cases be authorised for anyone to market. “Of course, that’s not an incentive for companies to invest in a lot of safety investigations for the product. It will really depend on what companies can do to protect their intellectual property. If the return on investment is not certain, there will be some companies who don’t invest,” said Patrick Coppens.
Dr Steffi Dudek, Senior Scientific Consultant at analyze & realize, also expressed concerns. “The new regulations certainly represent progress for traditional foods from third countries or for relatively simple products – exotic berries for example. But manufacturers of innovative synthetic or fermented ingredients who got authorisation under the old regulation after investing heavily in research will be disappointed that their proprietary data is not respected in the way we had hoped. I’m also concerned that some products that should be subject to their own authorisation might enter the EU market under a generic authorisation. It remains to be seen how companies will take the responsibility to assess the status of their products.”